Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
17
ANEB Quote, Financials, Valuation and Earnings
Last price:
$0.75
Seasonality move
:
2.01%
Day range:
$0.75 - $0.94
52-week range:
$0.30 - $3.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.95x
Volume:
6.3K
Avg. volume:
71.1K
1-year change:
-34.78%
Market cap:
$23.4M
Revenue:
--
EPS (TTM):
-$0.19
Analysts' Opinion
-
Consensus RatingAnebulo Pharmaceuticals, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.00, Anebulo Pharmaceuticals, Inc. has an estimated upside of 300% from its current price of $0.75.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $0.75.
Fair Value
-
According to the consensus of 1 analyst, Anebulo Pharmaceuticals, Inc. has 300% upside to fair value with a price target of $3.00 per share.
ANEB vs. S&P 500
-
Over the past 5 trading days, Anebulo Pharmaceuticals, Inc. has underperformed the S&P 500 by -26.7% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Anebulo Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Anebulo Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Anebulo Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Anebulo Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Anebulo Pharmaceuticals, Inc. reported earnings per share of -$0.05.
Enterprise value:
21.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.69x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-64.22%
Net Income Margin (TTM):
--
Return On Equity:
-69.07%
Return On Invested Capital:
-69.07%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$10.7M | -$8M | -$9.1M | -$2.6M | -$2.6M | |
| EBITDA | -$10.7M | -$8M | -$9.1M | -$2.6M | -$2.6M | |
| Diluted EPS | -$0.41 | -$0.29 | -$0.19 | -$0.09 | -$0.05 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19M | $16.9M | $6.8M | $15.4M | $9.3M | |
| Total Assets | $19M | $16.9M | $7.5M | $15.8M | $9.4M | |
| Current Liabilities | $49.9K | $1.4M | $1M | $878.8K | $1.5M | |
| Total Liabilities | $49.9K | $1.4M | $1M | $878.8K | $1.5M | |
| Total Equity | $18.9M | $15.5M | $6.5M | $15M | $7.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$9.6M | -$6.6M | -$5.8M | -$1.4M | -$1.3M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -$130.5K | $15M | -$116.7K | $15M | -- | |
| Free Cash Flow | -$9.6M | -$6.6M | -$5.8M | -$1.4M | -$1.3M | |
ANEB
Sector
Market Cap
$23.4M
$23.9M
Price % of 52-Week High
21.93%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
0.28%
-1.88%
1-Year Price Total Return
-34.78%
-18.29%
Beta (5-Year)
--
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.95
200-day SMA
Sell
Level
$1.80
Bollinger Bands (100)
Sell
Level
0.54 - 2
Chaikin Money Flow
Buy
Level
76.1K
20-day SMA
Sell
Level
$0.80
Relative Strength Index (RSI14)
Sell
Level
46.93
ADX Line
Sell
Level
21.2
Williams %R
Neutral
Level
-65.2304
50-day SMA
Buy
Level
$0.70
MACD (12, 26)
Buy
Level
0.21
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
181.8K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (62.8956)
Sell
CA Score
(Annual)
Level (-3.5095)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (32.6312)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
Stock Forecast FAQ
In the current month, ANEB has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ANEB average analyst price target in the past 3 months is $3.00.
-
Where Will Anebulo Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Anebulo Pharmaceuticals, Inc. share price will rise to $3.00 per share over the next 12 months.
-
What Do Analysts Say About Anebulo Pharmaceuticals, Inc.?
Analysts are divided on their view about Anebulo Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Anebulo Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Anebulo Pharmaceuticals, Inc.'s Price Target?
The price target for Anebulo Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $3.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ANEB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Anebulo Pharmaceuticals, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of ANEB?
You can purchase shares of Anebulo Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Anebulo Pharmaceuticals, Inc. shares.
-
What Is The Anebulo Pharmaceuticals, Inc. Share Price Today?
Anebulo Pharmaceuticals, Inc. was last trading at $0.75 per share. This represents the most recent stock quote for Anebulo Pharmaceuticals, Inc.. Yesterday, Anebulo Pharmaceuticals, Inc. closed at $0.75 per share.
-
How To Buy Anebulo Pharmaceuticals, Inc. Stock Online?
In order to purchase Anebulo Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ANEB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ANEB
Sector
P/E ratio
--
21.37x
PEG ratio
--
-0.01x
P/B ratio
2.95x
1.72x
Price / LTM sales
--
1.45x
Growth Metrics
ANEB
Sector
Revenue growth
--
3.44%
Earnings growth
45.77%
15.03%
Revenue (5-year growth)
--
6.25%
Earnings forecast
-$0.05
-$0.22
Profitability
ANEB
Sector
Profitability FY 2025
--
$2.4M
Return on invested capital
-69.07%
-33.32%
Return on assets
-64.22%
-29.45%
Return on equity
-69.07%
-40.29%
Earnings Date
Last Earnings Date
Sep
24
Next Earnings Date
Apr
4
Estimated Next Earnings Date
Jul
4
Balance Sheet
ANEB
Sector
Total cash
$9M
$25.7M
Short term investments
--
$22.7M
Total assets
$12.1M
$70.6M
Long term debt
--
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
